Medpace Holdings, Inc. (MEDP)
USD 305.11
(0.95%)
USD 305.11
(0.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 336.82 Million USD | 20.86% |
| 2022 | 278.69 Million USD | 40.32% |
| 2021 | 198.61 Million USD | 18.9% |
| 2020 | 167.04 Million USD | 31.26% |
| 2019 | 127.26 Million USD | 25.94% |
| 2018 | 101.04 Million USD | 55.8% |
| 2017 | 64.85 Million USD | 23.56% |
| 2016 | 52.49 Million USD | 58.7% |
| 2015 | 33.07 Million USD | 27.21% |
| 2014 | 26 Million USD | -55.83% |
| 2013 | 58.86 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 112.27 Million USD | 6.77% |
| 2024 Q2 | 105.15 Million USD | 1.04% |
| 2024 Q1 | 104.06 Million USD | 19.18% |
| 2023 Q3 | 84.9 Million USD | 8.31% |
| 2023 Q2 | 78.39 Million USD | -9.06% |
| 2023 Q1 | 86.2 Million USD | 12.79% |
| 2023 FY | 336.82 Million USD | 20.86% |
| 2023 Q4 | 87.32 Million USD | 2.84% |
| 2022 Q3 | 77.82 Million USD | 29.2% |
| 2022 Q1 | 64.2 Million USD | 17.04% |
| 2022 FY | 278.69 Million USD | 40.32% |
| 2022 Q4 | 76.43 Million USD | -1.79% |
| 2022 Q2 | 60.23 Million USD | -6.18% |
| 2021 Q1 | 47.59 Million USD | -13.44% |
| 2021 FY | 198.61 Million USD | 18.9% |
| 2021 Q2 | 42.44 Million USD | -10.82% |
| 2021 Q4 | 54.85 Million USD | 2.13% |
| 2021 Q3 | 53.71 Million USD | 26.54% |
| 2020 Q3 | 46.42 Million USD | 54.08% |
| 2020 FY | 167.04 Million USD | 31.26% |
| 2020 Q4 | 54.98 Million USD | 18.45% |
| 2020 Q2 | 30.12 Million USD | -15.14% |
| 2020 Q1 | 35.5 Million USD | -1.7% |
| 2019 Q1 | 25.89 Million USD | -15.56% |
| 2019 FY | 127.26 Million USD | 25.94% |
| 2019 Q4 | 36.11 Million USD | 20.43% |
| 2019 Q3 | 29.99 Million USD | -14.94% |
| 2019 Q2 | 35.25 Million USD | 36.16% |
| 2018 Q3 | 26.91 Million USD | 15.31% |
| 2018 FY | 101.04 Million USD | 55.8% |
| 2018 Q4 | 30.66 Million USD | 13.92% |
| 2018 Q2 | 23.34 Million USD | 16.03% |
| 2018 Q1 | 20.11 Million USD | 30.33% |
| 2017 Q4 | 15.43 Million USD | -10.24% |
| 2017 Q3 | 17.19 Million USD | 5.65% |
| 2017 Q2 | 16.27 Million USD | 2.1% |
| 2017 Q1 | 15.94 Million USD | 23.69% |
| 2017 FY | 64.85 Million USD | 23.56% |
| 2016 Q3 | 12.61 Million USD | -10.61% |
| 2016 Q4 | 12.89 Million USD | 2.16% |
| 2016 FY | 52.49 Million USD | 155.28% |
| 2016 Q2 | 14.11 Million USD | 9.67% |
| 2016 Q1 | 12.86 Million USD | 94.28% |
| 2015 Q4 | 6.62 Million USD | -37.48% |
| 2015 Q3 | 10.59 Million USD | 34.68% |
| 2015 Q2 | 7.86 Million USD | 23.13% |
| 2015 Q1 | 6.38 Million USD | 0.0% |
| 2015 FY | 20.56 Million USD | -20.92% |
| 2014 FY | 26 Million USD | -55.83% |
| 2014 Q1 | 1.83 Million USD | 0.0% |
| 2013 FY | 58.86 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 445.969% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 3175.103% |
| Aspira Women's Health Inc. | -18.85 Million USD | 1886.68% |
| Biodesix, Inc. | -41.34 Million USD | 914.728% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | 13086.835% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 4324.45% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 4324.45% |
| Bionano Genomics, Inc. | -215.24 Million USD | 256.484% |
| CareDx, Inc | -101.9 Million USD | 430.545% |
| Check-Cap Ltd. | -19.28 Million USD | 1846.384% |
| Castle Biosciences, Inc. | -67.97 Million USD | 595.498% |
| DarioHealth Corp. | -56.18 Million USD | 699.45% |
| Exact Sciences Corporation | -215.01 Million USD | 256.654% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 563.34% |
| Guardant Health, Inc. | -564.72 Million USD | 159.644% |
| ICON Public Limited Company | 956.15 Million USD | 64.773% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 69.299% |
| Illumina, Inc. | -1.06 Billion USD | 131.508% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 3375.496% |
| iSpecimen Inc. | -11.16 Million USD | 3115.619% |
| Standard BioTools Inc. | -76.6 Million USD | 539.719% |
| MDxHealth SA | -27.32 Million USD | 1332.572% |
| 23andMe Holding Co. | -321.35 Million USD | 204.814% |
| Myriad Genetics, Inc. | -123.7 Million USD | 372.292% |
| Mainz Biomed B.V. | -26.64 Million USD | 1364.136% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 3301.535% |
| NeoGenomics, Inc. | -107.73 Million USD | 412.639% |
| Neogen Corporation | 58.66 Million USD | -474.169% |
| Inotiv, Inc. | -81.46 Million USD | 513.485% |
| Natera, Inc. | -446.24 Million USD | 175.48% |
| OPKO Health, Inc. | -157.02 Million USD | 314.51% |
| Psychemedics Corporation | -2.92 Million USD | 11631.154% |
| Prenetics Global Limited | -52.51 Million USD | 741.406% |
| Prenetics Global Limited | -52.51 Million USD | 741.406% |
| Precipio, Inc. | -7.62 Million USD | 4520.276% |
| Personalis, Inc. | -109.93 Million USD | 406.383% |
| RadNet, Inc. | 98.69 Million USD | -241.272% |
| Sera Prognostics, Inc. | -39.82 Million USD | 945.848% |
| Sotera Health Company | 276.69 Million USD | -21.733% |
| Neuronetics, Inc. | -30.55 Million USD | 1202.392% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 7850.23% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 7850.23% |
| Trinity Biotech plc | -27.04 Million USD | 1345.424% |
| Twist Bioscience Corporation | -220.83 Million USD | 252.526% |
| Exagen Inc. | -22.83 Million USD | 1574.909% |